Venous Thromboembolism Treatment Market to be Worth $4.40 Billion by 2030 - Exclusive Report by Meticulous Research® [Yahoo! Finance]
First patient implanted with Philips' Duo Venous stent system [Yahoo! Finance]
AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval [Yahoo! Finance]
Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years [Yahoo! Finance]
AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.